Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model

Published: Tuesday, May 21, 2013
Last Updated: Monday, May 20, 2013
Bookmark and Share
New in vitro human living skin equivalent model for testing inflammatory responses.

Epistem and ScandiDerma have announced that they aim to develop a new in vitro human living skin equivalent model for testing inflammatory responses.

This is a novel method that will add to the field of dermatological testing as a whole and help create more activity in extracting high value compounds from biomass.

The collaboration is made possible through the UK's innovation agency, the Technology Strategy Board, and Innovation Norway following a successful application for funding in the "Sustainable high value chemical manufacture through industrial biotechnology" competition.

Matthew Walls, Epistem CEO commented "The collaboration with ScandiDerma presents an exciting opportunity to leverage Epistem's strong scientific background in skin biology and inflammation to address the shortage of robust human dermatology models for testing inflammatory responses.

"For ScandiDerma this is an important milestone in building up our competence around test-systems and how to rapidly determine good lead candidates from our bioprospecting activities" Ingebjorg Pernille Nedal, CEO ScandiDerma.

The project will last from May 2013 to March 2014 and will run from the project leader Epistem's facilities in Manchester UK and ScandiDerma's facilities in Barents Biocenter, Tromso, Norway.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem and CRT Announce Agreement
Agreement for the use of patient derived leukemic Primagraft samples.
Friday, May 01, 2015
Epistem Announces Executive Board Appointments
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.
Monday, January 27, 2014
Epistem Announces Partnership with The University of Manchester
Partnership will allow Epistem to expand its wound healing models range.
Monday, November 14, 2011
Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
New method for maintaining plucked human hairs ex vivo, and treating with therapeutic agents to obtain information on the cellular response to drug treatment.
Friday, November 19, 2010
EpiStem Awarded Further Long Term Funding for NIH Biodefence Programme
The Company has been reappointed for up to five years to provide preclinical testing services as a subcontractor.
Wednesday, November 10, 2010
Epistem’s Biomarker Division Gains GCLP Accreditation
Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organizations.
Tuesday, June 08, 2010
Epistem’s Biomarker Focus in the US
Epistem Inc to maximize the awareness of Epistem Plc’s technology offering as well as support the commercialization of the GenetRx™ biomarker platform.
Friday, October 30, 2009
Epistem Presents Further Data Supporting its Plucked Hair Biomarker Technology
Data on the effects of Gemcitabine on epithelial tissue released at the Institute of Cancer Research Centenary Conference.
Thursday, June 11, 2009
Scientific News
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Genome Engineering Paves Way For Sickle Cell Cure
Researchers from UC Berkeley have used CRISPR-Cas9 gene editing to fix the mutated gene responsible for sickle cell disease.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
Link Between Heart and Blood Cells in Early Development Found
Researchers have identifed a key factor in determining the fate of early undifferentiated cells during development.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos